Malignant Lung Neoplasm

In an in vitro study, a NCI-H1975 cell line expressing EGFR L858R and EGFR T790M co-mutation, EGFR T790M was associated with reduced sensitivity to erlotinib treatment compared to QG56 cells expressin… (full text at CIViC)

PMID 25853010 · Abourbeh et al., 2015 · Open in CIViC

In an in vitro study, a MCF-7 cell line expressing EGFR L858R and T790M co-mutation demonstrated resistance to erlotinib treatment, compared to MCF-7 cells expressing a known erlotinib sensitizing mut… (full text at CIViC)

PMID 21132006 · Harada et al., 2011 · Open in CIViC

In an NSCLC patient initially with L858R mutation, pemetrexed and cisplatin combination treatment was followed by erlotinib treatment. A slow progression developed which was found to be positive for L… (full text at CIViC)

PMID 24636847 · Li et al., 2014 · Open in CIViC

In non-small cell lung cancer, the appearance of T790M mutation leads to resistance to gefitinib.

PMID 15728811 · Kobayashi et al., 2005 · Open in CIViC

In a study of 14 patients with progressive non-small cell lung cancer during gefitinib treatment, comparison of DNA sequences from the original diagnostic biopsy specimen and the post-treatment biopsy… (full text at CIViC)

PMID 17020982 · Kosaka et al., 2006 · Open in CIViC

155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to E… (full text at CIViC)

PMID 23470965 · Yu et al., 2013 · Open in CIViC

48 tumor samples from 41 patients with EGFR mutant lung adenocarcinoma that were resistant to tyrosine kinase inhibition by gefitinib (n=1) or erlotinib (n=40) underwent next generation sequencing (NG… (full text at CIViC)

PMID 27304188 · Belchis et al., 2016 · Open in CIViC

In a study of 6 patients with progressive non-small cell lung cancer during gefitinib or erlotinib therapy, comparison of DNA sequences from the original diagnostic biopsy specimen and a post-treatmen… (full text at CIViC)

PMID 15737014 · Pao et al., 2005 · Open in CIViC

Lung cancers can accumulate activating mutations in oncogenes such as EGFR. The common L858R EGFR mutation has been shown previously to be sensitive to small molecular tyrosine kinase inhibitors (ie. … (full text at CIViC)

PMID 18227510 · Yun et al., 2008 · Open in CIViC

In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase… (full text at CIViC)

PMID 18408761 · Li et al., 2008 · Open in CIViC

An in vitro study treated Ba/F3 murine cells (IL-3 dependent lymphocyte model) to afatinib, a second-generation tyrosine kinase inhibitor (TKI), for several weeks. Secondary resistant mutations to afa… (full text at CIViC)

PMID 40940797 · Oiki et al., 2025 · Open in CIViC

Clinical study confirmed a beneficial effect from the combination therapy of MEK inhibitors and naquotinib. Inhibited cell proliferation in both naquotinib-resistant and osimertinib-resistant cells, … (full text at CIViC)

PMID 29386539 · Ninomiya et al., 2018 · Open in CIViC

The NSCLC cell line NCI-H1975 carrying the EGFR T790M mutation was resistant to erlotinib but showed increased sensitivity to HKI-272 (neratinib, IC50: 0.29 μmol/L). In an in vitro study Ba/F3 cells t… (full text at CIViC)

PMID 16818618 · Shimamura et al., 2006 · Open in CIViC

Osimertinib has been approved for the treatment of EGFR T790M mutant NSCLC.

PMID 26729184 · Greig, 2016 · Open in CIViC

Randomized, international, open-label, phase 3 trial (NCT02151981) in 419 patients with T790M-positive advanced NSCLC and disease progression after first-line EGFR-TKI therapy. Patients were randomize… (full text at CIViC)

PMID 27959700 · Mok et al., 2017 · Open in CIViC

This phase I/II trial (NCT01802632) involved 253 non-small cell lung cancer patients with activating EGFR mutations, who had progressed on first generation tyrosine kinase inhibitor treatment, and wer… (full text at CIViC)

PMID 25923549 · Jänne et al., 2015 · Open in CIViC

This study summarized 9 EGFR-mutant patients from two clinical trials involving rociletinib (NCT01526928) and subsequent osimertinib (NCT01802632). 8 were T790M-positive prior to treatment with osimer… (full text at CIViC)

PMID 26720284 · Sequist et al., 2016 · Open in CIViC

In a prospective study (NCT01802632) of 253 locally advanced or metastatic, non-small cell lung cancer patients, patients with EGFR T790M mutations treated with osimertinib were associated with improv… (full text at CIViC)

PMID 25923549 · Jänne et al., 2015 · Open in CIViC

A 57-year old male with no significant smoking history presented with lung squamous cell carcinoma in the right lung. Oncomine Dx Target Test was done and revealed EGFR exon 19 deletion and de novo EG… (full text at CIViC)

PMID 37641467 · Maeda et al., 2023 · Open in CIViC

In a lung adenocarcinoma patient harboring an EGFR E746_A750 mutation and an acquired EGFR T790M co-mutation, EGFR T790M was associated with sensitivity to osimertinib monotherapy. Prior to the develo… (full text at CIViC)

PMID 26269204 · Planchard et al., 2015 · Open in CIViC

Cell line, xenograft, and transgenic models were used to establish Osimertinib as an inhibitor of both EGFR mutation sensitizing (L858M, del exon 19) and T790M resistance mutants. Preclinically, the d… (full text at CIViC)

PMID 24893891 · Cross et al., 2014 · Open in CIViC

For cells harboring EGFR T790M mutation, osimertinib and rociletinib showed potent inhibition compared to erlotinib or afatinib. This study performed drug response assays using five human NSCLC cell l… (full text at CIViC)

PMID 26515464 · Hirano et al., 2015 · Open in CIViC

In a phase1-2 study, patients with the T790M mutation were more sensitive to rocelitinib in comparison to patients with T790M-negative NSCLC.

PMID 25923550 · Sequist et al., 2015 · Open in CIViC

Recently, the development of the third-generation epidermal growth factor receptor-small molecule inhibitor (EGFR-TKI) rociletinib had failed. in May 2016, after receiving a negative reply from the … (full text at CIViC)

PMID 27785053 · Van Der Steen et al., 2016 · Open in CIViC

CO-1686 (Rociletinib) more effectively induced apoptosis in EGFR mutated (T790M and others) NSCLC cell lines than those harboring wildtype EGFR. CO-1686 also more effectively reduced tumor volume of m… (full text at CIViC)

PMID 24065731 · Walter et al., 2013 · Open in CIViC

In NSCLC containing a T790M mutation, staurosporine may be inhibitive of EGFR, especially when an L858R mutation is also present.

PMID 24658966 · Ai et al., 2014 · Open in CIViC

A 53-year-old Chinese man, a lifelong non-smoker, presented with chest tightness and pain. CT imaging revealed multiple small nodules in the right lower lobe of the lung. A biopsy confirmed stage IV l… (full text at CIViC)

PMID 38074875 · Xiang et al., 2023 · Open in CIViC

This phase 3 trial (NCT02151981) involved 419 patients with EGFR T790M mutant NSCLC who progressed after first-line EGFR inhibitor therapy (gefitinib, erlotinib, or afatinib) and were either treated w… (full text at CIViC)

PMID 27959700 · Mok et al., 2017 · Open in CIViC

Case report of a patient with stage IV lung adenocarcinoma and a 15–base pair deletion in EGFR exon 19. Partial response with erlotinib was achieved for 15 months after initial chemotherapy. After fur… (full text at CIViC)

PMID 26181354 · Yu et al., 2015 · Open in CIViC

The novel tyrosine kinase inhibitor (TKI) CH7233163 has been reported to effectively overcome osimertinib resistance mediated by the EGFR Del19/T790M/C797S triple mutation. In vitro evaluation using e… (full text at CIViC)

PMID 32943545 · Kashima et al., 2020 · Open in CIViC

Case report of a patient with stage IV lung adenocarcinoma and a 15–base pair deletion in EGFR exon 19. Partial response with erlotinib was achieved for 15 months after initial chemotherapy. After fur… (full text at CIViC)

PMID 26181354 · Yu et al., 2015 · Open in CIViC

A 53-year old man (non-smoker) presented with chest tightness and pain and was revealed to have stage IV lung adenocarcinoma with EGFR exon 19 deletion. The patient started first-line Erlotinib at 150… (full text at CIViC)

PMID 38074875 · Xiang et al., 2023 · Open in CIViC

A patient was initially diagnosed with stage IIIA lung adenocarcinoma with EGFR L858R and was treated with lobectomy and adjuvant pemetrexed and cisplatin. 20 months later the patient had recurrent di… (full text at CIViC)

PMID 35004270 · Wang et al., 2021 · Open in CIViC

In a study, 1 participant with stage IIIB lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have T847I mutation, and was treated with the 1st generation TKI gefitinib. The pati… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In a lung adenocarcinoma patient with EGFR L858R (a known sensitizing mutation to EGFR tyrosine kinase inhibitor) and EGFR T854A co-mutation, EGFR T854A was reported to be refractory to erlotinib trea… (full text at CIViC)

PMID 19010870 · Bean et al., 2008 · Open in CIViC

One case with presumably EGFR::USP42 fusion was mentioned in OrigiMed database of Chinese patients with lung adenocarcinoma. EGFR breakpoint in intron 27.

PMID 31064887 · Guan et al., 2019 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EGFR V742A demonstrated increased sensitivity to erlotinib treatment comparable to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). … (full text at CIViC)

PMID 19147750 · Kancha et al., 2009 · Open in CIViC

In a study, 1 participant with stage IV adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V742A mutation, and was treated with the 1st generation TKI gefitinib. The patient (M,… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In an advanced lung adenocarcinoma patient with EGFR V769A mutation, EGFR V769A was reported to be sensitive to erlotinib treatment. The patient was treated with 1st-line standard chemotherapy, radiot… (full text at CIViC)

PMID 24908064 · Xing et al., 2014 · Open in CIViC

In this meta-analysis of 7 clinical trials evaluating the efficacy of erlotinib, 1 patient with V769_770insASV had overall and progression-free survival of 642 days. From this and literature review it… (full text at CIViC)

PMID 26773740 · Klughammer et al., 2016 · Open in CIViC

A 60 year old female former smoker with 2 pack years and EGFR V769_D770insASV lung adenocarcinoma patient was given erlotinib as first line treatment, and had progressive disease as best response with… (full text at CIViC)

PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

An in vitro study treated Ba/F3 murine cells (IL-3 dependent lymphocyte model) to afatinib, a second-generation tyrosine kinase inhibitor (TKI), for several weeks. Secondary resistant mutations to afa… (full text at CIViC)

PMID 40940797 · Oiki et al., 2025 · Open in CIViC

In a study, 1 participant with stage IV adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V774A mutation, and was treated with the 1st generation TKI gefitinib. The patient (F,… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In a lung adenocarcinoma patient harboring EGFR V774_C775insHV mutation, EGFR V774_C775insHV was associated with lack of response to treatment with erlotinib monotherapy.

PMID 23371856 · Arcila et al., 2013 · Open in CIViC

MCF-7 cells were transduced with YFP tagged EGFR with D770_N771INSSVD mutation, or YFP EGFR wildtype, and stained for ectopic YFP EGFR and phospho-Akt as a readout for EGFR pathway activity. Increased… (full text at CIViC)

PMID 17877814 · de Gunst et al., 2007 · Open in CIViC

In a study, 1 participant with stage IV squamous cell lung carcinoma was sequenced at EGFR exons 18 to 21 and was found to have V774M mutation, and was treated with the 1st generation TKI erlotinib. T… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In a study, 1 participant with stage IIIB lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V834I mutation, and was treated with the 1st generation TKI gefitinib. The pati… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

In a study, 1 participant with stage IV lung adenocarcinoma was sequenced at EGFR exons 18 to 21 and was found to have V851I mutation, and was treated with the 1st generation TKI gefitinib. The patien… (full text at CIViC)

PMID 21531810 · Wu et al., 2011 · Open in CIViC

Using NGS, genomic profiling from tumor/plasma biopsies from 17,442 Chinese lung cancer patients was performed. EGFR::VSTM2A reported in 2/1053 recurrent kinase fusions in lung cancer (NSCLC, adenocar… (full text at CIViC)

PMID 34508169 · Li et al., 2021 · Open in CIViC